Late Relapse and Reinfection in HCV Patients Treated with Direct-Acting Antiviral (DAA) Drugs

The risk of hepatitis C virus (HCV) recurrence after direct-acting antiviral (DAA) treatment is <0.5%. However, the distinction between HCV RNA late relapse and reinfection still represents a challenge in virological diagnostics. The aim of this study was to employ next-generation sequencing (NGS...

Descripción completa

Detalles Bibliográficos
Autores principales: Minosse, Claudia, Gruber, Cesare E. M., Rueca, Martina, Taibi, Chiara, Zaccarelli, Mauro, Grilli, Elisabetta, Montalbano, Marzia, Capobianchi, Maria R., Antinori, Andrea, D’Offizi, Gianpiero, McPhee, Fiona, Garbuglia, Anna Rosa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235384/
https://www.ncbi.nlm.nih.gov/pubmed/34208646
http://dx.doi.org/10.3390/v13061151

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235384/
https://www.ncbi.nlm.nih.gov/pubmed/34208646
http://dx.doi.org/10.3390/v13061151

Ejemplares similares